GleamWall
中文EN

AVBP ArriVent BioPharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1868279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-11.7%
TTM EPS YoY13.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.4%
ROA-45.5%
ROIC (approx.)-60.6%
Asset turnover—

Leverage & solvency

Liabilities / assets5.7%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$5.00M———————
R&D expense$38.90M$42.34M$37.62M$32.17M$32.17M$27.72M$61.29M$20.16M
SG&A expense$9.48M$10.35M$8.49M$6.65M$6.15M$5.90M$5.48M$3.54M
Operating income-$43.38M-$52.69M-$46.11M-$38.82M-$38.32M-$33.62M-$66.77M-$23.70M
Net income-$40.31M-$49.89M-$43.32M-$35.54M-$34.98M-$31.40M-$64.39M-$20.63M
EBITDA-$44.03M-$53.21M-$46.67M—————
EPS (basic)-0.81-1.05-0.96—-0.83-0.90-1.90—
EPS (diluted)-0.81-1.05-0.96—-0.83-0.90-1.90—
Weighted avg. shares (diluted)49.53M47.61M45.07M—41.91M35.01M33.90M—
Balance sheet
Cash & equivalents$113.58M$154.68M$62.10M$45.54M$112.67M$112.77M$49.87M$74.29M
Short-term investments$279.64M$218.44M$264.28M$267.28M$187.59M$122.92M$126.21M$144.57M
Current assets$416.62M$394.17M$348.70M$332.90M$321.22M$250.15M$185.78M$226.98M
Total assets$417.09M$394.72M$349.30M$333.17M$326.56M$269.51M$215.50M$274.94M
Current liabilities—$27.84M$25.00M$25.95M$21.56M$19.64M$12.95M$17.27M
Total liabilities$23.61M$27.88M$25.32M$25.95M$21.56M$19.64M$12.95M$17.29M
Shareholders' equity$393.48M$366.84M$323.98M$307.22M$305.00M$249.87M$202.54M$257.65M
Shares outstanding51.21M48.32M45.31M42.45M40.85M37.49M34.04M33.71M
Cash flow statement
Operating cash flow-$40.71M-$39.58M-$41.89M-$30.66M-$35.80M-$26.12M-$68.01M-$16.15M
Investing cash flow-$60.65M$46.07M$3.58M-$71.20M-$50.76M$13.91M$36.82M—
Financing cash flow$60.26M$86.09M$54.87M$34.73M$86.47M$75.11M$6.76M$55,000
Depreciation & amortization-$653,000-$515,000-$559,000—————
Stock-based compensation$6.88M$6.67M$5.49M$3.22M$3.72M$3.31M$2.27M$952,000

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.